Send us Feedback

Dendreon (DNDN)
QUOTE AND NEWS
The Second Quarter’s Biggest Winners… and Losers
Contrarian Profits  Jul 3 
The second quarter of 2009 was filled with gains and plenty of plain. After looking at the quarter’s winners and losers, one thing is obvious, biotechs can make or break your portfolio. Sometimes the best way to see where you are going is to...
Dendreon initiated with "hold"
newratings.com  Jun 30 
NEW YORK, June 30 (newratings.com) - Analysts at Morgan Joseph initiate coverage of Dendreon Corp (ticker: DNDN) with a "hold" rating. [more]
Dendreon: Cash Out or Keep Riding Up?
Motley Fool  Jun 22 
Promo: Given the rise this year and Provenge's prospects, what should a prudent investor do?
Dendreon (DNDN) Enters Agreement With Henderson Corp of PA
StreetInsider.com  Jun 22 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Dendreon+%28DNDN%29+Enters+Agreement+With+Henderson+Corp+of+PA/4746721.html for the full story.
Dendreon (DNDN) NewsBite - DNDN Upgraded By McAdams Wright Ragen
Market Intelligence Center  Jun 22 
Dendreon (DNDN) was upgraded today by analysts at McAdams Wright Ragen and the stock is now at $24.90, down $1.18 (-4.52%) on volume of 3,277,094 shares traded. The analysts upgraded DNDN to Hold from Sell. Over the last 52 weeks the stock has...
Dendreon upgraded to "hold"
newratings.com  Jun 22 
McAdams Wright Ragen Upgrades Dendreon (DNDN) to Hold
StreetInsider.com  Jun 22 
Dendreon Is No Dot-Com Story ... Yet
Motley Fool  Jun 19 
It's a biotech thing.
Is Dendreon Just a Dot-Com Story at This Price?
Motley Fool  Jun 18 
The stock has had a really good year, but now it's time to lock in the gains.
Dendreon (DNDN) NewsBite - Citigroup Initiates DNDN at Buy
Market Intelligence Center  Jun 10 
Dendreon (NGM: DNDN) opened at $26.07. So far today, the stock has hit a low of $25.43 and a high of $26.21. DNDN is now trading at $25.44, down $0.17 (-0.66%). Over the last 52 weeks the stock has ranged from a low of $2.55 to a high of $27.40....
Dendreon initiated with "buy"
newratings.com  Jun 10 
Dendreon initiated with "buy"
newratings.com  Jun 5 
NEW YORK, June 5 (newratings.com) - Analysts at Deutsche Bank Securities initiate coverage of Dendreon (ticker: DNDN) with a "buy" rating. The target price is set to $36. [more]
Dendreon's Gold: What's Next for Provenge
TheStreet.com  May 20 
TheStreet.com talks to Dendreon's CEO and CFO about Provenge and its aftermath.
Suggest other news sources for this topic
Suggest a News Source
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
Close 
Thanks for your suggestion!
 
See All
BULLS: REASONS TO BUY

 
100% agree
 
U.S. health regulators amend trial design of Provenge

See All
BEARS: REASONS TO SELL
Bears: Reasons To Sell
Feeling Bearish? Be the first to explain why this would make a poor investment
See All (0)
RELATED WIKI ARTICLES

Related Articles

more ▼EditWIKI ANALYSIS
 
DNDN AT A GLANCE
 
 
 
 
 
 
 
 
Please install Flash Player to view this chart.

Dendreon Corporation (DNDN) is a biotechnology company with a focus on developing drugs for cancer. Its most advanced product is Provenge (Sipuleucel-T), a therapeutic vaccine candidate being developed for the treatment of prostate cancer. Provenge could have blockbuster potential if the ongoing clinical late-stage trial yields positive results. Dendreon will market Provenge in the U.S. on its own. And we expect Dendreon to announce a partner for Provenge in the rest of the world soon. Another important product under clinical development is APC-8024 (Lapuleucel-T, Neuvenge) for the treatment of breast, ovarian, and colorectal cancers. The company has no products on the market and derives its revenue entirely from collaborations with other companies. Based in Seattle, WA, the company employs nearly 150 people.



[edit] References

Retrieved from "http://www.wikinvest.com/stock/Dendreon_(DNDN)"
 
Worried about pump and dump?
We review changes
for stock spam
» read more
Want to make Wikinvest better?
We need your help,
contribute today
» learn how
Do you write software?
We are recruiting
the best engineers
» view jobs
Like Wikinvest?
Spread the word —
Tell your friends!
» spread the word
Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki